New drug KPT-330 tested in kids with tough leukemia

NCT ID NCT02091245

First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 20 times

Summary

This study tests a drug called KPT-330 in children and teens (ages 1 to 21) with leukemia that has returned or not responded to standard treatments. The main goal is to find the safest dose and understand side effects. The drug works by blocking a protein that helps leukemia cells survive, potentially killing them. This is an early-phase trial with 16 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Children's Healthcare of Atlanta

    Atlanta, Georgia, 30322, United States

  • Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Seattle Children's Hospital

    Seattle, Washington, 98101, United States

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

  • UCSF

    San Francisco, California, 94143, United States

Conditions

Explore the condition pages connected to this study.